Emily B. Schroeder, MD, PhD, MSPH

Clinician Investigator

Emily SchroederEmily B. Schroeder, MD, PhD, MSPH, is a Clinician Investigator at the Institute for Health Research. Her research focuses on diabetes surveillance, microvascular and macrovascular complications of diabetes, chronic kidney disease, and epidemiologic methods.

Dr. Schroeder completed her Master of Science in Public Health and doctoral training in epidemiology at the University of North Carolina at Chapel Hill, and trained in Internal Medicine at Duke University and in Endocrinology at the University of Colorado. She has an extensive background in epidemiology methods and chronic disease epidemiology, with much of her recent work focusing on the use of clinical and administrative databases in the assessment of the prevalence and quality of care of common chronic conditions, such as diabetes, chronic kidney disease, hypertension, and hyperlipidemia.

Dr. Schroeder is a practicing endocrinologist at Kaiser Permanente Colorado as well as an Affiliate Assistant Professor of Medication in the Department of Endocrinology, Metabolism, and Diabetes at the University of Colorado School of Medicine.

Selected Research

  • Outreach for Diabetes Prevention and Weight Management Programs

    The objectives of this study are to develop a typology of the unintended consequences of health system interventions through a consensus process focused on a systematic review of prior publications, and to develop an approach based on this typology that can help researchers and evaluators plans for and assess the unintended consequences of health system interventions.
    Funder: Colorado Permanente Medical Group
    Study End Date: 12/31/2017

  • CV Benefits and Safety of Glucose-Lowering Therapies in Adults with Diabetes

    This project uses modern comparative effectiveness statistical approaches, including new user designs and marginal structural modeling with inverse probability weighting and targeted minimal loss-based estimation, to study the cardiovascular benefits and safety of glucose-lowering therapies in adults with diabetes.
    Funder:National Heart, Lung, & Blood Institute
    Study End Date: 5/31/2018

  • The Preventing Early Renal Function Loss (PERL) Allopurinol Study
    The objective of this multicenter, double-blind, placebo-controlled randomized clinical trial is to determine whether lowering serum uric acid by means of allopurinol early in the course of kidney disease may be effective in preventing or slowing the decline of renal function in patients with type 1 diabetes.
    Funder: National Institute of Diabetes and Digestive and Kidney Diseases
    Study End Date: 6/30/2018

  • Blood Pressure and Progression of Diabetic Kidney Disease

    Diabetic kidney disease is a major cause of morbidity, mortality and heath care costs in the United States. This project explores the treatment of blood pressure in the progression of diabetic kidney disease. The overarching objective of this career development award is to foster the development of Dr. Emily Schroeder, MD, PhD, into a leader improving the health and quality of life of individuals with diabetes.
    Funder: National Institute of Diabetes and Digestive and Kidney Diseases
    Study End Date: 6/30/2019